

Close

Quantity in Feb

Jan: 22,302

Variance: **▼** -1<u>8.8%</u>

COGS in Feb

\$844.6K

Jan: 1,122,122

Variance: ▼ -24.7%

Revenue in Feb

\$4.7M

Jan: 6,298,615

Variance: ▼-26.0%

Profit in Feb

\$3.8M

Jan: 5,176,493

Variance: ▼-26.2%

% Profit Margin in Feb

81.89%

Jan: ▲+82.2%







Bottom

5

8.1% of #Transaction is come from least sold 5 Drugs


5-Under Performing Drugs by #Transaction



Bottom Top

6.2% of #Transaction is come from least sold 5 Customers

5-Under Performing Customers by #Transaction



77 Out of 1251 of #Transaction

Drug Sales Report(Customer Analysis)

#Customers

200

Мар

Avg. Revenue

340K

Total Revenue

\$68.0M









Canada and Australia made up of 66.24% Revenue share

Chart







Revenue Analysis by Buyer
Type

\$59.8M

Seller Revenue

88%

\$8.19M

User Revenue

12%

Revenue By Gender

Male Female



\$31.7M



\$14.32M

Others

69.0% of Revenue share is attributed to 51+ and 31-40

Revenue by Age Group



Drug Sales Report(Trend Analysis)

Seller User


Open Filter #Transaction Total Revenue \$27.0M


Total Revenue by Year Total Revenue by Qtr \$24M \$7.3M \$6.6M \$6.8M \$6.3M \$1M \$1M 2022 2023 2024 Q-1 Q-2 Q-3 Q-4

















Heatmap



Revenue By Age-Group

Total Revenue is \$6,79,94,617.3

